Arondite | $12,000,000 | (May 2, 2025)
SafeHeal | $39,548,022 | (May 2, 2025)
Ceto | $4,800,000 | (May 2, 2025)
oncgnostics GmbH
Germany
- Jena, Thüringen
- 11/09/2023
- Unknown
- Undisclosed Amount
oncgnostics develops – based on proprietary epigenetic biomarkers - highly reliable molecular in vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in cancer diagnostics.
- Industry Biotechnology Research
- Website https://www.oncgnostics.com/
- LinkedIn https://www.linkedin.com/company/oncgnostics/about/
Related People
Martina SchmitzFounder
Germany -
Jena, Thuringia
oncgnostics develops – based on proprietary epigenetic biomarkers - highly reliable molecular in vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in cancer diagnostics.
First product is our CE IVD marked test "GynTect", a 2nd-line test for reliably detecting cervical cancer.
A short comic (german) explains what GynTect is doing.
On the Seedmatch-platform, there are a lot of insides on our company (german) and two nice videos about our company.
2016: https://www.seedmatch.de/startups/oncgnostics-2
2017: https://www.seedmatch.de/startups/oncgnostics
Gruve | $20,000,000 | (May 2, 2025)
Peek(US) | $5,000,000 | (May 2, 2025)
ChiroHD | $26,000,000 | (May 2, 2025)
Paramark.com | $8,000,000 | (May 2, 2025)
Zoe Financial | $30,000,000 | (May 2, 2025)
Hoofprint Biome | $15,000,000 | (May 2, 2025)
Stately Bio | $12,000,000 | (May 2, 2025)
SatLeo Labs | $3,300,000 | (May 2, 2025)
QbDVision | $13,000,000 | (May 2, 2025)